|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Malignant Melanoma - High Hurdles, High Rewards, Are Vaccines Only Skin Deep?
Datamonitor, April 2004, Pages: 159
Although the incidence of melanoma is only 5% of non-melanoma skin cancer, it accounts for three times as many deaths per year. High unmet need exists, with current treatments failing patients due to melanoma’s high resistance.
This Report examines current treatment trends and key issues, with insight into the pipeline drugs that may significantly alter future treatment and market dynamics.
Scope of Report:
Disease overview, including incidence to 2011, unmet needs, risk factors, screening and diagnosis
Analysis of current treatment, including surgery, immunotherapy, vaccines and combination therapies. Includes product profiles of key drugs by class
Report Highlights:
Debate continues between the US and Europe over the use of high-dose interferon-alpha as adjuvant therapy. Vaccines to induce anti-tumor responses are currently under development, with Canvaxin showing the most promise. It is expected that a vaccine will eventually replace interferon-alpha in the adjuvant setting.
Reasons to Purchase:
Identify future market opportunities by examining current unmet needs and how treatments are failing patients
Improve your promotional effectiveness through greater insight into diagnosis and treatment patterns and the preferences of physicians and specialists
Scope of Report:
Evaluation of pipeline products, including clinical trial information, commercial potential and limiting factors, with sales forecasts to 2012
Interview transcripts from our qualitative interviews with key opinion leaders in the US and Europe
Report Highlights:
No standard of care exists for stage IV melanoma patients, therefore most are treated on clinical trials. Novel compounds that target signal transduction pathways will most likely replace traditional chemotherapy. Antiangiogenesis agents, in particular BAY 43-9006 and Avastin (bevacizumab) are currently generating great interest.
Options for treating secondary brain metastases are a major unmet need among oncologists. Few options exist at this stage, with patients showing a particularly poor prognosis. Great interest is being shown in the combination of temozolomide and thalidomide as a potential treatment.
Reasons to Purchase:
Identify the most promising products in the pipeline, and track how current players are seeking to optimize their future market share
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Stakeholder Opinions: Melanoma - Lucrative Commercial Opportunities Persist
Melanoma Therapeutics: Which Strategy Will Take Us There?
Niche Cancers 2001: Melanoma
Strategic Perspectives: Malignant Melanoma - Biotechnology-Driven Agents Finding a Flagship Indication?
Currently Druggable in Melanoma: A Drug Target Competitive Analysis
Disease and Therapy Review: Melanoma
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
U.S. Emerging Melanoma Therapeutics Markets
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Competitor Analysis: Interferon
|
|
|
|
